Lisdexamfetamine Dimesylate Tablet, Chewable
Product Images NDC 72205-136

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72205-136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lisdex-dimesy-chew-tabs-10mg-100s-cntr-label (Lisdex Dimesy Chew Tabs 10mg 100s Cntr Label)

Label for Lisdexamfetamine Dimesylate Chewable Tablets, 10 mg strength, by Novadoz Pharmaceuticals LLC. The label includes directions to chew tablets completely, contains 100 chewable tablets, and provides storage instructions. Manufacturer is MSN Pharmaceuticals Inc., with distribution by Novadoz Pharmaceuticals LLC in Piscataway, NJ.*

FDA Label Image

Lisdex-dimesy-chew-tabs-20mg-100s-cntr-label (Lisdex Dimesy Chew Tabs 20mg 100s Cntr Label)

Lisdexamfetamine Dimesylate Chewable Tablets 20 mg label indicating 100 chewable tablets. The label includes instructions to chew tablets completely before swallowing and dispense with an accompanying Medication Guide. Manufactured by MSN Pharmaceuticals Inc and distributed by Novadoz Pharmaceuticals LLC. Storage instructions and barcodes are also visible.*

FDA Label Image

Lisdex-dimesy-chew-tabs-30mg-100s-cntr-label (Lisdex Dimesy Chew Tabs 30mg 100s Cntr Label)

Label for Lisdexamfetamine Dimesylate Chewable Tablets, 30 mg, by Novadoz Pharmaceuticals LLC. The label includes instructions to dispense the accompanying medication guide, advises chewing tablets completely before swallowing, and indicates a package size of 100 chewable tablets. Storage instructions and manufacturer/distributor information are also present.*

FDA Label Image

Lisdex-dimesy-chew-tabs-40mg-100s-cntr-label (Lisdex Dimesy Chew Tabs 40mg 100s Cntr Label)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 40 mg, manufactured by MSN Pharmaceuticals Inc and distributed by Novadoz Pharmaceuticals LLC. The label includes directions to chew tablets completely before swallowing and to dispense the accompanying Medication Guide. It also indicates packaging of 100 chewable tablets and provides storage instructions and contact details for Novadoz Pharmaceuticals.*

FDA Label Image

Lisdex-dimesy-chew-tabs-50mg-100s-cntr-label (Lisdex Dimesy Chew Tabs 50mg 100s Cntr Label)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 50 mg. The label states it is Rx only and includes directions to chew tablets completely before swallowing. It indicates a package size of 100 chewable tablets. The label lists MSN Pharmaceuticals Inc as manufacturer and Novadoz Pharmaceuticals LLC as distributor, with storage instructions and a website for the medication guide.*

FDA Label Image

Lisdex-dimesy-chew-tabs-60mg-100s-cntr-label (Lisdex Dimesy Chew Tabs 60mg 100s Cntr Label)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 60 mg by Novadoz Pharmaceuticals LLC. The label states it contains 100 chewable tablets and includes storage instructions, manufacturer and distributor information, barcode, and medication guide advisory. The label is primarily white with purple highlights and black text.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-01 (Lisdex Dimesy Chew Tabs Fig 01)

A forest plot chart depicting pharmacokinetic fold changes (Cmax and AUC) and 90% confidence intervals for lisdexamfetamine dimesylate in various special populations. It compares changes relative to reference values for subgroups based on gender, age (65-74 years and 75+ years), and degrees of renal impairment (mild, moderate, severe, end stage renal disease).*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-02 (Lisdex Dimesy Chew Tabs Fig 02)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Lisdexamfetamine dimesylate when co-administered with Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference from 0.0 to 2.0, with data points and confidence intervals plotted for each drug interaction.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-03 (Lisdex Dimesy Chew Tabs Fig 03)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of different interacting drugs relative to a reference. It plots variables including Cmax and AUC for drugs like Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, and Midazolam, grouped by metabolic pathways (CYP1A2, CYP2D6, CYP2C19, CYP3A). The x-axis indicates change relative to reference from 0.0 to 2.0.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-04 (Lisdex Dimesy Chew Tabs Fig 04)

A line graph comparing LS mean SKAMP deportment scores over time post-dose in hours, for Lisdexamfetamine dimesylate versus placebo. The graph shows two curves with error bars, illustrating the changes in scores over approximately 13 hours.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-05 (Lisdex Dimesy Chew Tabs Fig 05)

A line graph depicting the proportion of subjects with relapsed treatment failure over time (days after randomization) comparing Lisdexamfetamine Dimesylate and placebo groups. The x-axis represents time in days, and the y-axis shows the proportion of subjects experiencing treatment failure.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-06 (Lisdex Dimesy Chew Tabs Fig 06)

A line graph comparing Lisdexamfetamine dimesylate with placebo over time. The x-axis represents time post-dose in hours, from -0.5 to 14 hours, and the y-axis shows LS Mean (SE) PERMP Total Scores. Lisdexamfetamine dimesylate shows higher scores than placebo throughout the post-dose period, with error bars indicating variability.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-07 (Lisdex Dimesy Chew Tabs Fig 07)

A Kaplan-Meier curve graph comparing the proportion of subjects with the highest treatment failure over time after randomization for placebo versus Lisdexamfetamine dimesylate. The x-axis represents time in days, and the y-axis represents the proportion of subjects. The placebo curve shows higher treatment failure compared to the Lisdexamfetamine dimesylate curve throughout the observed period.*

FDA Label Image

Lisdex-dimesy-chew-tabs-fig-08 (Lisdex Dimesy Chew Tabs Fig 08)

A Kaplan-Meier survival curve comparing the probability of subjects with relapse over time between Lisdexamfetamine dimesylate and placebo groups. The x-axis represents time in days after randomization, and the y-axis shows the percentage of subjects with relapse, highlighting a difference in relapse rates between the two groups throughout the study period.*

FDA Label Image

Lisdex-dimesy-chew-tabs-structure (Lisdex Dimesy Chew Tabs Structure)

Chemical structure diagram of Lisdexamfetamine dimesylate, showing its molecular components including the active amine groups and the dimesylate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.